| Basics |
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings.
|
| IPO Date: |
June 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$1.23B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.40 | 1.68%
|
| Avg Daily Range (30 D): |
$0.55 | 2.12%
|
| Avg Daily Range (90 D): |
$0.49 | 1.89%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.25M |
| Avg Daily Volume (30 D): |
.33M |
| Avg Daily Volume (90 D): |
.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
65 |
| Avg Trade Size (Sh.) (30 D): |
41 |
| Avg Trade Size (Sh.) (90 D): |
42 |
| Institutional Trades |
| Total Inst.Trades: |
2,434 |
| Avg Inst. Trade: |
$1.79M |
| Avg Inst. Trade (30 D): |
$1.62M |
| Avg Inst. Trade (90 D): |
$1.72M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.07M |
| Avg Closing Trade (30 D): |
$1.64M |
| Avg Closing Trade (90 D): |
$1.96M |
| Avg Closing Volume: |
69.02K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.38
|
$.66
|
|
Diluted EPS
|
|
$.37
|
$.64
|
|
Revenue
|
$
|
$ 191.84M
|
$ 174.41M
|
|
Gross Profit
|
$
|
$ 98.65M
|
$ 86.49M
|
|
Net Income / Loss
|
$
|
$ 17.35M
|
$ 31.03M
|
|
Operating Income / Loss
|
$
|
$ 25.32M
|
$ 42.18M
|
|
Cost of Revenue
|
$
|
$ 93.19M
|
$ 87.92M
|
|
Net Cash Flow
|
$
|
$ 28.58M
|
$ 4.91M
|
|
PE Ratio
|
|
|
|
|
|
|
